Download PDF
Thromb Haemost 1989; 62(02): 742-747
DOI: 10.1055/s-0038-1646894
Original Article
Schattauer GmbH Stuttgart

Characterization of Monoclonal Antibodies to Human Tissue-Type Plasminogen Activator: Catalytic Inhibition and One-Two Chain Discriminatory Reactivities

Torgny Stigbrand
The Department of Physiological Chemistry, University of Umei, Umeå, Sweden
,
Lars Frängsmyr
The Department of Physiological Chemistry, University of Umei, Umeå, Sweden
,
Nils Bergsdorf
The Department of Physiological Chemistry, University of Umei, Umeå, Sweden
,
Per Wallen
The Department of Physiological Chemistry, University of Umei, Umeå, Sweden
› Author Affiliations
Further Information

Publication History

Received 06 January 1989

Accepted after revision 27 April 1989

Publication Date:
30 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A new set of monoclonal antibodies was generated against the tissue plasminogen activator (t-PA). One of the antibodies, 1:3 C5, was found to be able to distinguish between the one- and two-chain form of t-PA and also exerted significant amidolytic inhibitory activity. Several of the antibodies, as judged from their binding properties in immunosorbent tests, were found to be suitable for immunoaffinity purification purposes, i.e. 1:3C5, 1:3 G5, and 1:2 B9. Three of the mabs, 1:2 B9, 1:3 G5 and 2:2 BIO, were selectively reactive with the A-chain of t-PA, whereas indirect evidences indicated 1:3 C5 to be reactive with a conformational epitope on the B-chain. Three of the antibodies were reactive with porcine t-PA. This new set of antibodies should prove useful for structure-function investigations of t-PA.

Keywords

Tissue plasminogen activator - Fibrinolysis - Monoclonal antibodies
 

  • References

  • 1 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedGoogle Scholar
  • 2 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
    CrossrefPubMedGoogle Scholar
  • 3 Thorsen S, Glas-Greenwalt P, Astrup T. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diath Haemorrh 1972; 28: 65-74
    PubMedGoogle Scholar
  • 4 Wallén P. Structure and function of tissue plasminogen activator and urokinase. In: Fundamental and Clinical Fibrinolysis. Castellino et al. (eds) Academic Press; New York: 1987: 1-18
    Google Scholar
  • 5 Hoylaerts M, Rijken DC, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-2919
    PubMedGoogle Scholar
  • 6 Rånby M. Studies on kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704: 461-469
    CrossrefPubMedGoogle Scholar
  • 7 Weimar W, Stibbe J, Vanseyen AJ, Billian A, Desomer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 1981; 2: 1018-1020
    PubMedGoogle Scholar
  • 8 Korninger C, Matsuo O, Suy R, Stassen JM, Collen D. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 1982; 69: 573-580
    CrossrefPubMedGoogle Scholar
  • 9 Bergmann SR, Fox KA A, Terpogossian MM, Sobel BE, Collen D. Clot selective coronary thrombolysis with tissue type plasminogen activator. Science 1983; 220: 1181-1183
    CrossrefPubMedGoogle Scholar
  • 10 Van de Werf F, Bergmann SR, Fox KA, de Geest H, Hoyng CF, Sobel BE, Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1984; 69: 605-610
    CrossrefPubMedGoogle Scholar
  • 11 Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, Verstraete M, Collen D, Sobel B. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Eng J Med 1984; 310: 609-613
    CrossrefPubMedGoogle Scholar
  • 12 Wallen P, Rånby M, Bergsdorf N, Kok P. Purification and characterization of tissue plasminogen activator; on the occurrence of two different forms and their enzymatic properties. In: Progress in Fibrinolysis. Davidson JF, Nilsson IM, Asted B. (eds) (; 5). Churchill Livingstone; Edinburgh: 1981: 229-232
    Google Scholar
  • 13 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E.coli. . Nature 1983; 301: 214-221
    CrossrefPubMedGoogle Scholar
  • 14 Banyai L, Varadi A, Patthy L. Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator. FEBS Lett 1983; 163: 37-41
    CrossrefPubMedGoogle Scholar
  • 15 MacGregor IR, Micklem LR, James K, Pepper DS. Characterization of epitopes on human tissue plasminogen activator recognised by a group of monoclonal antibodies. Thromb Haemostas 1985; 53: 45-50
    PubMedGoogle Scholar
  • 16 Holvoet P, Lijnen HR, Collen D. Characterization of functional domains in human tissue-type plasminogen activation with the use of monoclonal antibodies. Eur J Biochem 1986; 158: 173-177
    CrossrefPubMedGoogle Scholar
  • 17 Holvoet P, Boes J, Collen D. Measurement of free, one-chain, tissue- type plasminogen activator in human plasma with an enzymelinked immunosorbent assay based on an active site-specific murine monoclonal antibody. Blood 1987; 69: 284-289
    PubMedGoogle Scholar
  • 18 Matsuo O, Tanhara Y, Okada K, Bundo H, Nagoya T. Monoclonal antibody to human tissue-plasminogen activator. Thromb Res 1984; 36: 517-526
    CrossrefPubMedGoogle Scholar
  • 19 Tahada A, Shizume K, Ozawa T, Takahashi S, Takada Y. Characterization of various antibodies against tissue plasminogen activator using highly sensitive enzyme immunoassay. Thromb Res 1986; 42: 63-72
    CrossrefPubMedGoogle Scholar
  • 20 Wallén P, Pohl G, Bergsdorf N, Rånby M, Ny T, Jornvall H. Purification and characterization of a melanoma cell plasminogen activator. Eur J Biochem 1983; 132: 681-686
    CrossrefPubMedGoogle Scholar
  • 21 Wallén P, Bergsdorf N, Rånby M. Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin. Biochim Biophys Acta 1982; 719: 318-328
    CrossrefPubMedGoogle Scholar
  • 22 Ichinose A, Takio K, Fujikawa K. Localization of the binding site of tissue-type plasminogen activator to fibrin. J Clin Invest 1986; 78: 163-169
    CrossrefPubMedGoogle Scholar
  • 23 Rijken DC, Groenevelt E. Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator. J Biol Chem 1986; 261: 3096-3102
    PubMedGoogle Scholar
  • 24 Kearny J, Radbruch F, Liesegang B, Rajewsky K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 1979; 123: 1548-1550
    PubMedGoogle Scholar
  • 25 Uotila M, Engvall E, Rouslahti E. Monoclonal antibodies to human alpha-feto protein. Mol Immunol 1980; 17: 791-794
    CrossrefPubMedGoogle Scholar
  • 26 Chalon MP, Milne RW, Vaerman IP. Interactions between mouse immunoglobulins and staphylococcal protein A. Scand J Immunol 1979; 9: 359-364
    CrossrefPubMedGoogle Scholar
  • 27 Carlsson L, Folkersen J, Stigbrand T. Antigenic determinants of pregnancy-associated α2-glycoprotein and α2-macroglobulin defined by poly- and monoclonal antibodies. Mol Immunol 1985; 22: 1073-1080
    CrossrefPubMedGoogle Scholar
  • 28 Lau HKF, Lui AY Y, Wong NS. Identification of plasmin as the major contaminant in immunoglobulin preparations. Comp Biochem Physiol 1986; 84B: 507-511
    PubMedGoogle Scholar
  • 29 Norrman B, Pohl G, Jomvall H, Wallen P. Proteolytically induced variations in the enzymatic properties of tissue plasminogen activator. Eur J Biochem 1986; 159: 7-13
    CrossrefPubMedGoogle Scholar
  • 30 Rånby M, Suensen E, Bergsdorf N, Norrman B, Wallen P. Tissue plasminogen activator kinetics. Prog Fibrinolys 1983; 6: 182-184
    PubMedGoogle Scholar
  • 31 Rånby M, Norrman B, Wallen P. A sensitive assay for tissue plasminogen activator. Thromb Res 1982; 77: 743-749
    PubMedGoogle Scholar
  • 32 Norrman B, Wallén P, Rånby M. Fibrinolysis mediated by tissue plasminogen activator: Disclosure of a kinetic transition. Eur J Biochem 1985; 149: 193-200
    CrossrefPubMedGoogle Scholar
  • 33 Deutsch DG, Mertz ET. Plasminogen: Purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
    CrossrefPubMedGoogle Scholar
  • 34 Wallén P, Wiman B. Characterization of human plasminogen. Biochim Biophys Acta 1972; 257: 122-134
    CrossrefPubMedGoogle Scholar
  • 35 Norrman BA, Frangsmyr LC, Stigbrand T, Wallen PB. A monoclonal antibody to tissue plasminogen activator with affinity for the Kringle regions: Implications for fibrin affinity and enzymatic mechanism. Fibrinolysis 1987; 1: 135-142
    PubMedGoogle Scholar
  • 36 Liu CY, Handley DA, Wallen P, Smith J. Fibrin potentiation of plasminogen activation by tissue plasminogen activator on bovine endothelial cell surface. Abstract No. 98 The 8th International Congress on Fibrinolysis; Vienna: 1986
    Google Scholar
  • 37 Wallén P, Pohl G, Bergsdorf N, Rånby M, Jörnvall H. Purification and characterization of a melanoma cell plasminogen activator. Eur J Biochem 1983; 132: 681-686
    CrossrefPubMedGoogle Scholar
  • 38 van Zonneveld AJ, Veerman H, Brakenhoff JP J, Aarden LA, Cajot F, Pannekoek H. Mapping of epitopes on human tissue-type plasminogen activator with recombinant deletion mutant proteins. Thromb Haemostas 1987; 57: 82-86
    PubMedGoogle Scholar
  • 39 Wallén P, Bergsdorf N, Pohl G, Stigbrand T. Differentiation between one-chain and two-chain tissue type plasminogen activator by monoclonal antibodies. Haemostasis 1984; 14: 42
    PubMedGoogle Scholar